BamSEC and AlphaSense Join Forces
Learn More

Annovis Bio Inc.

NYSE: ANVS    
Share price (1/8/25): $5.16    
Market cap (1/8/25): $71.2 million

Material Contracts Filter

EX-10.1
from 8-K 10 pages Separation Agreement and General Release
12/34/56
EX-10.2
from 8-K 29 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 75 pages Common Stock Purchase Agreement Dated as of April 25, 2024 by and Among Annovis Bio, Inc., and Keystone Capital Partners, LLC
12/34/56
EX-10.6
from 10-K 8 pages Recitals
12/34/56
EX-10.2
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 42 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 12 pages Annovis Bio, Inc. Warrant to Purchase Common Stock
12/34/56
EX-10.6
from 10-K 8 pages Recitals
12/34/56
EX-10.1
from 8-K 11 pages Separation Agreement and General Release
12/34/56
EX-10.1
from 8-K 6 pages Mr. Henry Hagopian, III 56 Robert Road Stow, Ma 01775 Re: Employment Offer Dear Henry: On Behalf of Annovis Bio, Inc. (The “Company”), I Am Pleased to Offer You Employment as Chief Financial of the Company, Reporting to the Company’s Chief Executive Officer or Her Designee. the Purpose of This Letter Is to Set Forth the Terms of the Offer. 1. Position; Duties
12/34/56
EX-10.1
from 10-Q 14 pages Wilmington Pharmatech Proposal #: Wpt-210203-06r5
12/34/56
EX-10.9
from 10-K 12 pages Employment Agreement
12/34/56
EX-10.1
from 10-K 12 pages Second Amended and Restated Employment Agreement
12/34/56
EX-10.8
from S-1/A 14 pages Form of Annovis Bio, Inc. 2019 Equity Incentive Plan
12/34/56
EX-10.5
from S-1/A 11 pages Qr Pharma, Inc. Registration Rights Agreement
12/34/56
EX-10.7
from S-1 11 pages Investigator-Initiated Clinical Trial Agreement
12/34/56
EX-10.6
from S-1 2 pages License Agreement Amendment Number 2
12/34/56
EX-10.4
from S-1 14 pages License Agreement Amendment
12/34/56
EX-10.3
from S-1 23 pages License Agreement
12/34/56
EX-10.2
from S-1 13 pages Annovis Bio, Inc. 2018 Equity Incentive Plan
12/34/56